ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0080309 | The hemodynamic and electrophysiological action of the HEART VENTRICLES. | Function, Ventricular|ventricular function|Ventricular Functions|Functions, Ventricular | Ventricular Function |
C0872383 | null | GRK|G protein-coupled receptor kinase (GRK)|grk | G protein-coupled receptor kinase (GRK) |
C0015697 | null | Fatty Streak, Arterial|Streak, Arterial Fatty|Arterial Fatty Streaks|Arterial Fatty Streak|Fatty Streaks, Arterial|Streaks, Arterial Fatty | Arterial Fatty Streak |
C1516312 | Endogenous and exogenous compounds and that either inhibit CASPASES or prevent their activation. | Caspase Blockers|Caspase Inhibitor|Blockers, Caspase|Inhibitors, Caspase | Caspase Inhibitors |
C0383779 | null | ZVAD-fluoromethylketone|Z-Val-Ala-Asp-fluoromethylketone|Z-VAD.FMK|ZVAD-FMK|Z-VAD-FMK|carbobenzoxyvalyl-alanyl-aspartyl fluoromethyl ketone | benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone |
C0383779 | null | ZVAD-fluoromethylketone|Z-Val-Ala-Asp-fluoromethylketone|Z-VAD.FMK|ZVAD-FMK|Z-VAD-FMK|carbobenzoxyvalyl-alanyl-aspartyl fluoromethyl ketone | benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone |
C0003009 | An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. | Angiotensin-(1-8) Octapeptide|angiotensin ii|ANG-(1-8)Octapeptide|Angiotensin 2|2 angiotensin|angiotensin 2|angiotensin II|isoleucine5-angiotensin II|Angiotonin|ANGIOTENSIN II|Angiotensin II|Product containing angiotensin II (medicinal product)|Angiotensin II-containing product|Angiotensin II (substance)|5-L-isoleucineangiotensin II | angiotensin II |
C0242546 | A stereoisomer of yohimbine. | null | Rauwolscine |
C0296215 | null | BIBP-3226|BIBP3226 | BIBP 3226 |
C0194133 | null | perfusion renal|Local perfusion of kidney|renal perfusion|Local perfusion of kidney (procedure) | Local perfusion of kidney |
C0879444 | A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have become resistant (unable to respond) to. Tariquidar is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist. | tariquidar|Tariquidar|tariquidarth|TARIQUIDAR | tariquidar |
C1567656 | null | ELACRIDAR|Elacridar | Elacridar |
C1373059 | null | Opioid Agonists [MoA] | Opioid Agonists |
C0443310 | An electroencephalograph is a device used to measure and record the electrical activity of the patient's brain obtained by placing two or more electrodes on the head. | ELECTROENCEPHALOGRAPH|Standard electroencephalogram machine|electroencephalograph|Electroencephalograph|encephalograph|eeg machine|Standard electroencephalogram machine (physical object)|Electroencephalograph (physical object)|eeg machines | Standard EEG machine |
C0079784 | A mononuclear phagocyte colony-stimulating factor (M-CSF) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. M-CSF is a disulfide-bonded glycoprotein dimer with a MW of 70 kDa. It binds to a specific high affinity receptor (RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR). | MCSF|macrophage colony-stimulating factor (M-CSF)|m-csf|Colony-stimulating factor, macrophage (substance)|CSF-1|Colony Stimulating Factor 1|CSF-M|Colony-stimulating factor 1|Colony Stimulating Factor, Macrophage|Colony-Stimulating Factor, Macrophage|M-CSF|Colony-stimulating factor, macrophage|Macrophage Colony-Stimulating Factor|Colony-Stimulating Factor 1 | Macrophage Colony-Stimulating Factor |
C0040028 | A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets. | Essential thrombocytosis|Thrombocythemias, Idiopathic|Thrombocythemias, Primary|Idiopathic (hemorrhagic) thrombocythemia|Essential thrombocythemia (clinical disorder)|Essential Thrombocytemia|essential thrombocythaemia|idiopathic thrombocythemia|hemorrhagic thrombocythemia|Essential thrombocythemia|thrombocythemia essential|Primary thrombocytosis|Essential Thrombocythemias|Hemorrhagic Thrombocythemia|Thrombocythemias, Hemorrhagic|Idiopathic thrombocythemia|THROMBOCYTHEMIA, ESSENTIAL, WITH HEMORRHAGIC DIATHESIS|Primary Thrombocythemias|ESSENTIAL THROMBOCYTHEMIA|THROMBOCYTHEMIA, HEMORRHAGIC|Idiopathic hemorrhagic thrombocythemia|THROMBOCYTHEMIA, IDIOPATHIC|Thrombocythemias, Essential|ET|Essential Thrombocythemia|Primary Thrombocythemia|thrombocytosis essential|Idiopathic Thrombocythemias|Essential haemorrhagic thrombocythaemia|Thrombocytosis, Primary|Thrombocythemia, Essential|essential thrombocythemia|Essential hemorrhagic thrombocythemia|Essential thrombocythemia (disorder)|Thrombocythemia, Idiopathic|thrombocythemia, essential|Primary Thrombocytosis|primary thrombocythemia|Primary thrombocythaemia|essential thrombocytosis|Essential thrombocythaemia|THROMBOCYTHEMIA IDIOPATHIC|Primary thrombocythemia|THROMBOCYTHEMIA, PRIMARY HEMORRHAGIC|Thrombocythemia, Hemorrhagic|Idiopathic haemorrhagic thrombocythaemia|idiopathic thrombocytosis|Primary Thrombocytoses|Essential thrombocythemia (morphologic abnormality)|Idiopathic thrombocythaemia|Essential Thrombocytosis|Thrombocytoses, Primary|Idiopathic Thrombocythemia|Thrombocythemia, Primary|primary thrombocytosis|Hemorrhagic Thrombocythemias | Thrombocythemia, Essential |
C0032463 | A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs. | POLYCYTHEMIA RUBRA VERA|ERYTHREMIA|OSLER-VAQUEZ DISEASE|Polycythaemia vera (clinical)|PPP - Primary proliferative polycythaemia|PV|PRV - Polycythemia rubra vera|splenomegalic polycythemia|POLYCYTHEMIA, SPLENOMEGALIC|Erythremias|Proliferative polycythaemia|Polycythemia Rubra Veras|polycythemia vera|Polycythemia Vera|Ruba Vera, Polycythemia|Erythremia|erythraemia|Polycythaemia rubra vera|Vera, Polycythemia Ruba|p.vera|p vera|VAQUEZ-OSLER DISEASE|POLYCYTHEMIA VERA|polycythemia ruba vera|Veras, Polycythemia Ruba|Polycythemias, Primary|PRV|Polycythemia Rubra Vera|erythremia|Primary Polycythemia|Polycythaemia vera|polycythemia rubra vera|Primary Polycythemias|Vera, Polycythemia Rubra|Primary polycythaemia|Polycythemia Ruba Veras|Veras, Polycythemia Rubra|erythrocythemia|proliferative polycythemia|Polycythemia, Primary|Ruba Veras, Polycythemia|Vaquez's disease|Polycythemia rubra vera|PPP - Primary proliferative polycythemia|Polycythemia vera (disorder)|Proliferative polycythemia|Primary proliferative polycythaemia|polycythaemia vera|Polycythemia Ruba Vera|osler's disease|Polycythemia vera (clinical)|Osler-Vaquez Disease|vaquez's disease|polycythaemia rubra vera|Osler-Vaquez syndrome|primary polycythemia|Polycythemia vera|Disease, Osler-Vaquez|Osler's disease|Primary proliferative polycythemia|Osler Vaquez Disease|Polycythemia vera (morphologic abnormality)|PRV - Polycythaemia rubra vera|POLYCYTHEMIA, PRIMARY | Polycythemia Vera |
C1566164 | null | LBH589|NVP-LBH589|LBH 589|NVP LBH589|(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide | LBH589 |
C1517631 | The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises. The K562 line is composed of undifferentiated blast cells that are rich in glycophorin and may be induced to produce fetal and embryonic hemoglobin in the presence of hemin. | K562 blasts|K562 | K-562 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C1310018 | null | H2A histone family, member Y2 protein, human|macroH2A.2 histone protein, human|H2AFY2 protein, human | MACROH2A2 protein, human |
C1310018 | null | H2A histone family, member Y2 protein, human|macroH2A.2 histone protein, human|H2AFY2 protein, human | MACROH2A2 protein, human |
C0065400 | null | null | lysosomal proteins |
C1515406 | A recombinant form of the endogenous Transforming Growth Factor-Beta 1, a protein involved with the regulation of cell proliferation and differentiation. | TGFbeta1|Transforming Growth Factor-Beta 1|Transforming Growth Factor Beta-1|Recombinant Transforming Growth Factor-Beta 1|HUMAN TRANSFORMING GROWTH FACTOR .BETA.-1 | Recombinant Transforming Growth Factor-Beta 1 |
C0817124 | null | Anterior tubercle of left transverse process of third cervical vertebra|Anterior costal tubercle of left transverse process of third cervical vertebra | Anterior tubercle of left transverse process of third cervical vertebra |
C0817124 | null | Anterior tubercle of left transverse process of third cervical vertebra|Anterior costal tubercle of left transverse process of third cervical vertebra | Anterior tubercle of left transverse process of third cervical vertebra |
C0257133 | null | IBTC ligand|o-iodobenzyl-1-thio-beta-cellobioside | 2-iodobenzyl-1-thiocellobioside |
C0257133 | null | IBTC ligand|o-iodobenzyl-1-thio-beta-cellobioside | 2-iodobenzyl-1-thiocellobioside |
C0039215 | A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. | Lymphocyte, CD4-Positive|T4 Cells|CD4-Positive Lymphocytes|Cd4 Lymphocyte|lymphocytes cd4|cd4 cells|T4 lymphocyte|CD4 lymphocyte|cd4 lymphocyte|t4 cell|T-Lymphocyte, CD4-Positive|t4 cells|CD4 Positive T Lymphocytes|CD4-Positive T-Lymphocytes|CD4+ T-Lymphocyte|CD4-Positive Lymphocyte|CD4-positive T lymphocyte|T lymphocyte positive for CD4 antigen (cell)|CD4-Positive T-Lymphocyte|CD4+ T Lymphocyte|T-Lymphocytes, CD4-Positive|lymphocytes t4|cd4 lymphocytes|CD4 Lymphocytes|Lymphocytes, CD4-Positive|CD4 Lymphocyte|T4 Cell|CD4+ T Lymphocytes|cd4 cell|t4 lymphocyte|T4 Lymphocytes|T lymphocyte positive for CD4 antigen|T4 Lymphocyte | CD4 Positive T Lymphocytes |
C0525013 | A regulatory region first identified in the human beta-globin locus but subsequently found in other loci. The region is believed to regulate GENETIC TRANSCRIPTION by opening and remodeling CHROMATIN structure. It may also have enhancer activity. | Control Regions, Locus|Regions, Locus Control|Locus Control Regions|locus control region|Control Region, Locus|Region, Locus Control | Locus Control Region |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C1282910 | In a place or position that is higher. | Superior|Superior (qualifier value)|superior|SUPERIOR|supra|supra-|above|Supra-|Supra- (qualifier value)|Upper (qualifier value)|Above|upper|UPPER|Upper | Upper |
C0007818 | The circulation of blood through the BLOOD VESSELS of the BRAIN. | CBF|Cerebral Circulation|cerebral blood flow|Cerebral Circulations|Cerebral circulation|Cerebrovascular Circulation|cerebrovascular circulation|blood flow cerebral|blood cerebral flow|Cerebral Blood Flow|Circulations, Cerebral|Circulation, Cerebral|Circulation, Cerebrovascular|cerebral circulation | Cerebrovascular Circulation |
C0007785 | The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction). | Cerebral infarcts|Cerebral Ischemia|Cerebral Infarctions|cerebral infarctions|Cerebral Infarction|cerebral infarct|Cerebral infarction|Infarctions, Cerebral|cerebral infarction|Cerebral infarction (disorder)|Infarct, Cerebral|Cerebral vascular infarction|infarct cerebral|Cerebral infarction, NOS|Cerebral Infarcts|CEREBRAL INFARCT|Cerebral infarct|Infarcts, Cerebral|infarction cerebral|CEREBRAL INFARCTION|cerebral infarcts|INFARCT CEREBRAL|Infarction, Cerebral|Cerebral, Infarction|Cerebral Infarct | Cerebral Infarction |
C1514241 | A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism. | POSITIVE|Positive Finding|Positive | Positive Finding |
C0116466 | A naturally occurring, fibrous mineral consisting of white, prismatic crystals. Erionite is one of the more common types of zeolites that are found in the earth's crust. This mineral is used as a metal-impregnated catalyst, as a fertilizer, to control odors in livestock production and is used in animal feed, pet litter and horticultural applications. Excessive inhalation of its dust can cause pulmonary fibrosis or silicatosis and prolonged exposure to erionite causes mesothelioma in humans. It is known to be a human carcinogen. (NCI05) | Erionite|Erionite (substance) | erionite |
C1377610 | A benign or malignant mesothelial neoplasm that arises from the peritoneum. | Mesothelioma of Peritoneum|Mesothelioma of the Peritoneum|Peritoneal Mesothelioma | Peritoneal Mesothelioma |
C0032149 | A protozoan parasite of rodents transmitted by the mosquito Anopheles dureni. | Plasmodium berghei|Plasmodium berghei (organism)|plasmodium berghei|berghei, Plasmodium|Plasmodium bergheus|rodent plasmodia | Plasmodium berghei |
C0056997 | An enzyme which catalyzes the deamination of CYTOSINE resulting in the formation of URACIL. It can also act on 5-methylcytosine to form THYMIDINE. | Cytosine Aminohydrolase|cytosine deaminase|Cytosine deaminase (substance)|Aminohydrolase, Cytosine|Deaminase, Cytosine|Cytosine Deaminase|Cytosine deaminase | Cytosine deaminase |
C0524689 | null | Lung Volume Reduction|lung volume reduction|Volume Reduction, Lung|Reduction, Lung Volume | Lung Volume Reduction (procedure) |
C1325696 | Protein complex that mediates editing of the mRNA encoding apolipoprotein B; catalyzes the deamination of C to U (residue 6666 in the human mRNA). Contains a catalytic subunit, APOBEC-1, and other proteins (e.g. human ASP; rat ASP and KSRP). [PMID:10781591] | apoB mRNA editing enzyme complex|apolipoprotein B mRNA editing enzyme complex location|APOBEC|apoB mRNA editing enzyme complex location | apolipoprotein B mRNA editing enzyme complex |
C0200316 | null | null | Electroacoustic evaluation for hearing aid, monaural |
C0520679 | A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395) | obstructive sleep osa apnea|Apnea, obstructive|Obstructive Sleep Apnea|OSA - Obstructive sleep apnea|OSA - Obstructive sleep apnoea|Obstructive sleep apnea (adult)(pediatric)|Obstructive apnea|APNEA, OBSTRUCTIVE SLEEP|OSA|apnea obstructive sleep|SLEEP APNEA/HYPOPNEA SYNDROME|Sleep Apneas, Obstructive|obstructive sleep apnea syndrome|SAHS|Obstructive sleep apnoea syndrome|Obstructive Sleep Apnea Syndrome|OSAS|Syndrome, Obstructive Sleep Apnea|Obstructive sleep apnea syndrome (disorder)|obstructive sleep apnoea|Apneas, Obstructive Sleep|Sleep Apnea, Obstructive|Apnea, Obstructive Sleep|Obstructive sleep apnea|Sleep Apnea Syndrome, Obstructive|Obstructive sleep apnoea|sleep apnea obstructive syndrome|Sleep Apnea Hypopnea Syndrome|obstructive sleep apnea|apnea obstructive sleeping|OSAHS|OBSTRUCTIVE SLEEP APNEA SYNDROME|Obstructive sleep apnea syndrome|Obstructive Apnea|Obstructive Sleep Apneas|Syndrome, Sleep Apnea, Obstructive | Sleep Apnea, Obstructive |
C0887901 | The main structural proteins of CAVEOLAE. Several distinct genes for caveolins have been identified. | Proteins, Caveolin|caveolin|Caveolins|Caveolin Proteins | Caveolins |
C0032225 | The thin serous membrane enveloping the lungs (LUNG) and lining the THORACIC CAVITY. Pleura consist of two layers, the inner visceral pleura lying next to the pulmonary parenchyma and the outer parietal pleura. Between the two layers is the PLEURAL CAVITY which contains a thin film of liquid. | pleura|Wall of pleural sac|PLEURAL TISSUE|Pleural membrane structure|Pleural structure|PLEURA|Pleura|Pleura, NOS|Pleural membrane structure (body structure)|Pleural Tissue|Pleural|Pleuro- | Pleura |
C0599921 | Lymphoid tissue located beneath the mucosal epithelia of those mucosal surfaces that have contact with the external environment, such as the respiratory, digestive, and urinary systems. MALT consists of a collection of predominantly small lymphocytes, fewer larger, transformed lymphocytes, and plasma cells. It protects the body from pathogens that enter via the mucosa. MALT gives rise to a distinctive type of B-cell lymphoma that usually follows an indolent clinical course. | MALT|Mucosa-Associated Lymphoid Tissue|Epithelio-lymphoid tissue|mucosa associated lymphoid tissue (MALT)|Mucosa-associated lymphoid tissue|Mucosa associated lymphoid tissue|MALT (mucosa associated lymphoid tissue)|malt|Lymphoid Tissue, Mucosa-associated | mucosa-associated lymphoid tissue |
C0340515 | null | dysfunction heart|Myocardial depression|heart dysfunction|myocardial dysfunction|Myocardial dysfunction (disorder) | Myocardial dysfunction |
C0349414 | null | Hypodynamic septicaemic shock|Cold septic shock|Hypodynamic septicemic shock|Hypodynamic septic shock (disorder) | Hypodynamic septic shock |
C0024115 | Pathological processes involving any part of the LUNG. | Lung disorder, NOS|lung diseases|DISEASES OF THE LUNG|Lung Diseases|lung disease|DISORDER LUNG|disease of lung|Pulmonary disease, NOS|Lung Disease|pneumopathy|Pulmonary Disease|Disease of lung, NOS|LUNG DISORDER|pulmonary diseases|pulmonary disease|pulmonary disorders|Disorder of lung (disorder)|Disorder of lung|Lung disease|Lung disease NOS|Disease, Lung|PULMONARY DISEASE|Disorder of Lung|Lung Disorders|Lung Disorder|Pulmonary Disorders|PULMONARY DISORDER|Diseases, Pulmonary|Pulmonary disease|diseases lungs|PULMONARY DISORDERS|diseases of the lung|Pulmonary Diseases|DISORDER PULMONARY|diseases pulmonary|lung disorder|disorders lung|lung disorders|Disease, Pulmonary|Diseases, Lung|Lungs--Diseases|LUNG DISORDER (NOS)|Lung disorder|pulmonary disorder|disorder lung|Pulmonary Disorder|disorders pulmonary | Lung diseases |
C0149711 | null | HILAR ADENOPATHY|adenopathy hilar | hilar adenopathy |
C0162323 | An arthritis affecting five or more separate joints. | polyarthritis|Polyarthritis, NOS|POLYARTHRITIS|Inflammatory arthritis of multiple joints|Inflammatory polyarthropathy or polyarthritis NOS|Polyarticular Arthritis|Unspecified inflammatory polyarthropathy|ARTHRITIS, MULTIPLE JOINT INVOLVEMENT|Inflammatory polyarthropathy (disorder)|Polyarthritis|Polyarthritides|inflammatory polyarthropathy|Inflammatory polyarthropathy|polyarticular arthritis|polyarthritides|Polyarticular arthritis|Inflammatory polyarthropathy, NOS|polyarthropathy inflammatory | Polyarthritis |
C0595726 | A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. | Product containing leukotriene receptor antagonist (product)|leukotriene receptor antagonist|leukotriene receptor antagonists|leukotriene antagonist|Antagonists, Leukotriene|Leukotriene Antagonists|leukotriene antagonists|Leukotriene receptor antagonist|Antagonists, Leukotriene Receptor|Receptor Antagonists, Leukotriene|Leukotriene receptor antagonist-containing product|Substance with leukotriene receptor antagonist mechanism of action (substance)|Substance with leukotriene receptor antagonist mechanism of action|Antileukotrienes|inhibitors leukotriene receptor|Leukotriene Receptor Antagonists | Leukotriene Antagonists |
C0595726 | A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. | Product containing leukotriene receptor antagonist (product)|leukotriene receptor antagonist|leukotriene receptor antagonists|leukotriene antagonist|Antagonists, Leukotriene|Leukotriene Antagonists|leukotriene antagonists|Leukotriene receptor antagonist|Antagonists, Leukotriene Receptor|Receptor Antagonists, Leukotriene|Leukotriene receptor antagonist-containing product|Substance with leukotriene receptor antagonist mechanism of action (substance)|Substance with leukotriene receptor antagonist mechanism of action|Antileukotrienes|inhibitors leukotriene receptor|Leukotriene Receptor Antagonists | Leukotriene Antagonists |
C0083725 | A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression. | Neurofibromatosis type 1 protein|Neurofibromatosis Type 1 Gene Product|neurofibromatosis type 1 protein|Neurofibromatosis Type 1 Protein|NF1 GRP|NF1-GAP-Related Protein|NF1 GAP Related Protein|neurofibromin|Neurofibromin 1|Neurofibromin (substance)|NF1 Protein|neurofibromatosis type 1 protein/gene|Neurofibromin|NF-1 Protein|NF1 protein|NF 1 Protein | Neurofibromatosis Type 1 Protein |
C0083725 | A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression. | Neurofibromatosis type 1 protein|Neurofibromatosis Type 1 Gene Product|neurofibromatosis type 1 protein|Neurofibromatosis Type 1 Protein|NF1 GRP|NF1-GAP-Related Protein|NF1 GAP Related Protein|neurofibromin|Neurofibromin 1|Neurofibromin (substance)|NF1 Protein|neurofibromatosis type 1 protein/gene|Neurofibromin|NF-1 Protein|NF1 protein|NF 1 Protein | Neurofibromatosis Type 1 Protein |
C0599177 | null | null | protein activation |
C0282625 | A PROTEIN-TYROSINE KINASE family that was originally identified by homology to the Rous sarcoma virus ONCOGENE PROTEIN PP60(V-SRC). They interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways. Oncogenic forms of src-family kinases can occur through altered regulation or expression of the endogenous protein and by virally encoded src (v-src) genes. | Tyrosine Kinases, src|src Protein-Tyrosine Kinases|src-Family Tyrosine Kinases|SRC Family Tyrosine Kinase|src Family Kinases|Tyrosine Kinases, src-Family|Protein-Tyrosine Kinases, src|src Kinases|src Family Tyrosine Kinases|Kinases, src|Kinases, src Tyrosine|src Tyrosine Kinases|Kinases, src Protein-Tyrosine | src-Family Kinases |
C0025706 | An alkylating agent in cancer therapy that may also act as a mutagen by interfering with and causing damage to DNA. | as-Dimethyl Sulfite|Methylmethane Sulfonate|Methanesulfonate, Methyl|Methanesulfonic Acid Methyl Ester|Mesilate, Methyl|Methanesulfonic acid, methyl ester|Methylmesilate|Methyl Methylenesulfonate|Methyl Mesilate|Methyl Methanesulfonate|Mesylate, Methyl|Methyl Mesylate|Methyl methanesulfonate|MMS|METHYL METHANESULFONATE | Methyl Methanesulfonate |
C0243037 | Genes that code for proteins that regulate the CELL DIVISION CYCLE. These genes form a regulatory network that culminates in the onset of MITOSIS by activating the p34cdc2 protein (PROTEIN P34CDC2). | Cell Cycle Genes|Cell Cycle Gene|Cell Division Cycle Genes|Genes, Cell Division Cycle|cdc Gene|cdc Genes | Genes, cdc |
C0005933 | Removal of bone tissue for microscopic examination. | bone biopsy|Biopsy of Bone|biopsy bone|biopsies bone|Biopsy of bone|Biopsy of bone, NOS|Biopsy of bone, unspecified site|biopsy of bone|Bone Biopsy|Bone biopsy|Biopsy of bone (procedure) | Biopsy of bone |
C1335934 | A basal cell carcinoma that arises from the scrotum. | Basal Cell Carcinoma of Scrotum|Basal Cell Carcinoma of the Scrotum | Scrotal Basal Cell Carcinoma |
C1335934 | A basal cell carcinoma that arises from the scrotum. | Basal Cell Carcinoma of Scrotum|Basal Cell Carcinoma of the Scrotum | Scrotal Basal Cell Carcinoma |
C0054799 | null | null | carmethizole |
C0054799 | null | null | carmethizole |
C0020305 | Abnormal accumulation of serous fluid in two or more fetal compartments, such as SKIN; PLEURA; PERICARDIUM; PLACENTA; PERITONEUM; AMNIOTIC FLUID. General fetal EDEMA may be of non-immunologic origin, or of immunologic origin as in the case of ERYTHROBLASTOSIS FETALIS. | Hydrops foetalis|fetal edema|HF - Hydrops fetalis|Hydrops Fetalis|hydrops fetal|Edema, Fetal|Fetal Hydrops|Hydrops fetalis (disorder)|Hydrops, Fetal|HF - Hydrops foetalis|Fetal Edema|Hydrops foetalis, NOS|fetal hydrops|hydrops foetalis|Hydrops fetalis|fetalis hydrops|Fetal hydrops|Hydrops fetalis, NOS|HYDROPS FETALIS|hydrops fetalis | Hydrops Fetalis |
C0001642 | A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems. | Adrenergic Receptors, beta-1|Adrenergic beta 1 Receptors|Receptors, Adrenergic beta-1|Beta-1 adrenergic receptor|beta 1 Adrenergic Receptors|Adrenergic beta-1 Receptors|Receptors, Adrenergic, beta-1|Beta-1 Adrenoreceptor|beta-1 Receptors, Adrenergic|Receptors, beta 1 Adrenergic|Beta 1 Receptor|Adrenergic Receptor, beta-1|Receptor, Adrenergic, beta-1|beta-1 Adrenergic receptor site|Receptors, beta-1 Adrenergic|Beta-1 adrenergic receptor (substance)|Receptor, beta-1 Adrenergic|Beta 1 Adrenergic Receptor|Beta-1-Adrenergic Receptor|Beta-1 Adrenoceptor|ADRB1|beta-1 Adrenergic Receptor|Beta-1 Adrenergic Receptor|beta 1 Adrenergic Receptor|Adrenergic Receptor, beta 1|beta-1 Adrenergic Receptors | Receptors, Adrenergic, beta-1 |
C0001642 | A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems. | Adrenergic Receptors, beta-1|Adrenergic beta 1 Receptors|Receptors, Adrenergic beta-1|Beta-1 adrenergic receptor|beta 1 Adrenergic Receptors|Adrenergic beta-1 Receptors|Receptors, Adrenergic, beta-1|Beta-1 Adrenoreceptor|beta-1 Receptors, Adrenergic|Receptors, beta 1 Adrenergic|Beta 1 Receptor|Adrenergic Receptor, beta-1|Receptor, Adrenergic, beta-1|beta-1 Adrenergic receptor site|Receptors, beta-1 Adrenergic|Beta-1 adrenergic receptor (substance)|Receptor, beta-1 Adrenergic|Beta 1 Adrenergic Receptor|Beta-1-Adrenergic Receptor|Beta-1 Adrenoceptor|ADRB1|beta-1 Adrenergic Receptor|Beta-1 Adrenergic Receptor|beta 1 Adrenergic Receptor|Adrenergic Receptor, beta 1|beta-1 Adrenergic Receptors | Receptors, Adrenergic, beta-1 |
C0751969 | Small nuclear RNAs that are involved in the processing of pre-ribosomal RNA in the nucleolus. Box C/D containing snoRNAs (U14, U15, U16, U20, U21 and U24-U63) direct site-specific methylation of various ribose moieties. Box H/ACA containing snoRNAs (E2, E3, U19, U23, and U64-U72) direct the conversion of specific uridines to pseudouridine. Site-specific cleavages resulting in the mature ribosomal RNAs are directed by snoRNAs U3, U8, U14, U22 and the snoRNA components of RNase MRP and RNase P. | RNA, Small Nucleolar|Small Nucleolar RNA|snoRNA | Small Nucleolar RNA |
C0752085 | Nucleolar RNA-protein complexes that function in pre-ribosomal RNA processing. | Small Nucleolar Ribonucleoproteins|snoRNP|Ribonucleoproteins, Small Nucleolar | Small Nucleolar Ribonucleoproteins |
C0246597 | null | proendothelin-1|proET-1 | proendothelin 1 |
C0246597 | null | proendothelin-1|proET-1 | proendothelin 1 |
C1334805 | Proteins found in any species or strain of mouse. | null | Mouse Protein |
C1334805 | Proteins found in any species or strain of mouse. | null | Mouse Protein |
C0023492 | A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood. | Lymphocytic Leukemia, T|t cell leukemia|Leukemia, Lymphocytic, T Cell|adult t cell leukemia|T-Cell Lymphocytic Leukemia|Lymphocytic Leukemias, T|T Lymphocytic Leukemia|t-cell lymphocytic leukemia|T Lymphocytic Leukemias|T-cell lymphocytic leukemia|T-Cell Leukemia|Leukemia, T Lymphocytic|Lymphocytic Leukemia, T Cell|Leukemia, Lymphocytic, T-Cell|t-cell leukemia|leukemia t-cell|Leukemias, T-Cell Lymphocytic|Lymphocytic Leukemias, T-Cell|Lymphocytic Leukemia, T-Cell|cells leukemia t|Leukemias, T-Lymphocytic|Leukemias, T-Cell|T-Cell Leukemias|T-Lymphocytic Leukemias|Leukemia, T-Cell|Leukemia, T-Lymphocytic|T-Cell Lymphocytic Leukemias|T-Lymphocytic Leukemia|T Cell Leukemia|Leukemia, T-Cell Lymphocytic|Leukemias, T Lymphocytic|leukemia t cell|adult t-cell leukemia|Leukemia, T Cell | Leukemia, T-Cell |
C0027362 | Persons classified by age from birth (INFANT, NEWBORN) to octogenarians and older (AGED, 80 AND OVER). | Age groups|Age Group|age group|human age group|age groups|Group, Age|Groups, Age|Age Groups | Human Age Group |
C0001021 | Enzyme that catalyzes the final step of fatty acid oxidation in which ACETYL COA is released and the CoA ester of a fatty acid two carbons shorter is formed. | beta Ketoacyl Thiolase|Thiolase, 2-Methylacetoacetyl CoA|Acyl-CoA:acetyl-CoA C-acyltransferase|Acetyl-CoA C-Acyltransferase|Acetyl-coenzyme A acyltransferase|beta Ketothiolase|Beta-ketothiolase|3-Ketoacyl-CoA thiolase|Thiolase, 3-Oxoacyl-Coenzyme A|3-ketoacyl-CoA thiolase|beta-Ketothiolase|Acetyl-CoA acyltransferase|Acyltransferase, Acetyl CoA|Acetyl coenzyme A acyltransferase|2-Methylacetoacetyl CoA Thiolase|3-Ketothiolase|CoA Thiolase, 3-Ketoacyl|Thiolase, 3-Oxoacyl CoA|3-Oxoacyl-Coenzyme A Thiolase|beta-Ketoacyl Thiolase|Thiolase, 3-Ketoacyl CoA|Acetyl-coenzyme A acyltransferase (substance)|Acetyl CoA C Acyltransferase|Acetyl CoA Acyltransferase|3-Ketoacyl CoA Thiolase|Acetyl Coenzyme A Acyltransferase|CoA Thiolase, 3-Oxoacyl|3-Oxoacyl CoA Thiolase|CoA Acyltransferase, Acetyl|CoA Thiolase, 2-Methylacetoacetyl|Thiolase, beta-Ketoacyl|C-Acyltransferase, Acetyl-CoA | Acetyl-CoA C-Acyltransferase |
C0057403 | null | d(ApGpCpT) | deoxy-(adenylyl-guanylyl-cytidylyl-thymidine) |
C0222677 | null | Osseous Cell|bones cells|Bone cells|Cell of bone|bone cell|Bone Cell|bone cells|Cell of bone (cell)|cells bone|cell of bone|Cell of bone, NOS | Cell of bone |
C0678727 | The earliest recognizable stage of development of an anatomical structure, tissue, organ or cell. | primordium|anlage|Primordium | Primordium |
C0348013 | Of, or pertaining to, or contained in, or performing the function of the veins. | Venous|venous|Venous (qualifier value) | Venous |
C0599220 | Single chains of amino acids that are the units of multimeric PROTEINS. Multimeric proteins can be composed of identical or non-identical subunits. One or more monomeric subunits may compose a protomer which itself is a subunit structure of a larger assembly. | Subunit|protein subunit|PROTEIN SUBUNIT|Subunits, Protein|Subunit, Protein|Protein Subunits|Protein Subunit | Protein Subunits |
C0079427 | Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible. | oncosuppressor gene|Tumor suppressor gene|Tumor Suppressing Genes|genes suppressor tumour|Gene, Tumor Suppressor|Recessive Oncogenes|antioncogene|Gene, Cancer Suppressor|Oncogene, Recessive|Tumor Suppressing Gene|Tumor Suppressor Gene|tumor suppressors|Emerogenes|Tumor Suppressor Genes|Oncogenes, Recessive|Suppressor Gene, Cancer|Tumor Suppressors|Recessive Oncogene|Tumour suppressor gene|Anti-Oncogenes|Gene, Onco-Suppressor|tumor suppressing gene|Emerogene|Antioncogene|Genes, Cancer Suppressor|Cancer Suppressor Gene|tumour suppressor gene|Anti-Oncogene|Gene, Tumor Suppressing|emerogene|Suppressor Genes, Cancer|Onco-Suppressor Genes|Tumor Suppressor|genes tumor suppressor|genes suppressor tumor|suppressor genes cancer|Anti Oncogenes|Antioncogenes|Onco-Suppressor Gene|recessive oncogenes|Genes, Tumor Suppressing|Antioncogene (substance)|Genes, Onco Suppressor|anti-oncogenes|tumor suppressor genes|tumor suppressor|Anti-oncogene|tumor suppressor gene|cancer suppressor gene|Genes, Tumor Suppressor|recessive oncogene|suppressor tumor|Cancer Suppressor Genes|Genes, Onco-Suppressor | Tumor Suppressor Genes |
C0816598 | null | Right ulna|right ulna | Right ulna |
C0816598 | null | Right ulna|right ulna | Right ulna |
C0140080 | A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain. | IGF 1 Receptor|Receptors, Insulin-Like-Growth Factor I|Receptors, IGF-1|IGF Type 1 Receptor|Receptor, IGF I|Receptor, IGF Type 1|IGF-I Receptor|Insulin-Like-Growth Factor I Receptor|IGF-1 Receptors|IGF I Receptor|Receptor, IGF-1|IGF1R|Receptor, Insulin-Like Growth Factor I|Receptor, IGF-I|IGF-1 Receptor|Receptor, Insulin-Like Growth Factor Type 1|Insulin Like Growth Factor I Receptor|Receptors, IGF 1|insulin-like growth factor I receptor | Insulin-Like-Growth Factor I Receptor |
C0140080 | A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain. | IGF 1 Receptor|Receptors, Insulin-Like-Growth Factor I|Receptors, IGF-1|IGF Type 1 Receptor|Receptor, IGF I|Receptor, IGF Type 1|IGF-I Receptor|Insulin-Like-Growth Factor I Receptor|IGF-1 Receptors|IGF I Receptor|Receptor, IGF-1|IGF1R|Receptor, Insulin-Like Growth Factor I|Receptor, IGF-I|IGF-1 Receptor|Receptor, Insulin-Like Growth Factor Type 1|Insulin Like Growth Factor I Receptor|Receptors, IGF 1|insulin-like growth factor I receptor | Insulin-Like-Growth Factor I Receptor |
C0035679 | A DNA-dependent RNA polymerase present in bacterial, plant, and animal cells. It functions in the nucleoplasmic structure and transcribes DNA into RNA. It has different requirements for cations and salt than RNA polymerase I and is strongly inhibited by alpha-amanitin. EC 2.7.7.6. | DNA Dependent RNA Polymerase II|Ribonucleic acid polymerase II|Ribonucleic acid polymerase II (substance)|RNA Polymerase B|RNA Polymerase II|POLR2|RNA polymerase II|DNA-Dependent RNA Polymerase II|RNA Pol II|Pol II|RNAP II | RNA Polymerase II |
C0004898 | Characteristics or attributes of persons or things which elicit pleasurable feelings. | beauty|beauties | Beauty |
C0427611 | The determination of the amount of the inhibition of blood coagulation in response to anticoagulant therapies. | Activated Coagulation Time|Whole blood activated clotting time|Activated clotting time|Coagulation time, activated|ACT|activated blood clotting time test|Ground glass clotting time|ACT - activated clotting time|activated coagulation time|Activated Clotting Time|activated clotting time|Coagulation time, activated (procedure) | Activated clotting time measurement |
C0051977 | null | Anti-Immunoglobulin D antibody (substance)|Anti-Immunoglobulin D antibody | anti-IgD |
C0051977 | null | Anti-Immunoglobulin D antibody (substance)|Anti-Immunoglobulin D antibody | anti-IgD |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.